“Experience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genes”, Onkologija, vol. 25, no. 1, pp. 12–16, May 2021, doi: 10.25670/oi2021-002on.